EKF DIAGNOSTICS HOLDINGS PLC (EKF) — Preliminary Results

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the EKF DIAGNOSTICS HOLDINGS PLC Preliminary Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press set. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Gavin Jones. Good morning to you. Good morning, everyone. Thanks for joining us for the EKF DIAGNOSTICS preliminary results for 2025. So in the room at the moment, I've got myself Gavin Jones and our CFO Steve Young. And just behind me, who you can't see, I'm hiding here, our exec chair, Julian Baines. So today I'd like to present to you once again the strategy. I think it's important for us to really keep hitting on that point. So form a, I think everyone would have seen this slide many, many times. Certainly we've seen it internally a lot because it's really important for us that it's understood where we're going and how we're going to get there. So targets 29 are to be number one in points of care hemoglobin, number one in ketone testing, VHP laboratory and point of care which would be something new for us and to transform our EKF life sciences entity into a truly positive contract development and manufacturing organization. From a point of care point of view, we're really working hard on developing The US blood bank business, expanding our NGO access, certainly in Africa and other markets and developing certain new territories in LatAm and APAC. From a BHB or ketone testing point of view, we are continuing to develop our BHB liquid color product and for improved performance criteria, new manufactur...